These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2833827)

  • 1. Cytomegalovirus infection complicating renal transplantation and its relationship to acute transplant glomerulopathy.
    Boyce NW; Hayes K; Gee D; Holdsworth SR; Thomson NM; Scott D; Atkins RC
    Transplantation; 1988 Apr; 45(4):706-9. PubMed ID: 2833827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients.
    Lewis RM; Johnson PC; Golden D; Van Buren CT; Kerman RH; Kahan BD
    Transplantation; 1988 Feb; 45(2):353-9. PubMed ID: 2830686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of treatment with cyclosporine versus azathioprine on incidence and severity of cytomegalovirus infection posttransplantation.
    Bia MJ; Andiman W; Gaudio K; Kliger A; Siegel N; Smith D; Flye W
    Transplantation; 1985 Dec; 40(6):610-4. PubMed ID: 3000031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of cytomegalovirus disease in cyclosporine-treated renal transplant recipients based on donor/recipient pretransplant immunity.
    Weir MR; Irwin BC; Maters AW; Genemans G; Shen SY; Charache P; Williams GM
    Transplantation; 1987 Feb; 43(2):187-93. PubMed ID: 3027930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
    Cristelli MP; Esmeraldo RM; Pinto CM; Sandes-Freitas TV; Felipe C; Lobo CF; Viana L; Mansur J; Stopa S; Santos DWC; Grenzi PC; Aguiar WF; Tedesco-Silva H; Pestana JOM
    Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glomerulopathy in renal allografts from patients with and without active Cytomegalovirus infection.
    Spencer ES; Jepsen FL
    Dan Med Bull; 1989 Jun; 36(3):300-1. PubMed ID: 2546717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
    Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
    Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus infection in a seroendemic renal transplant population: a longitudinal study of virological markers.
    Rao M; Finny GJ; Abraham P; Juneja R; Thomas PP; Jacob CK; Sridharan G
    Nephron; 2000 Apr; 84(4):367-73. PubMed ID: 10754415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of cytomegalovirus infection on seronegative recipients of seropositive donor kidneys versus seropositive recipients treated with cyclosporine-prednisone immunosuppression.
    Johnson PC; Lewis RM; Golden DL; Oefinger PE; Van Buren CT; Kerman RH; Kahan BD
    Transplantation; 1988 Jan; 45(1):116-21. PubMed ID: 2827353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus as a risk factor in living-related renal transplantation. A prospective study.
    Pollak R; Barber PL; Prusak BF; Mozes MF
    Ann Surg; 1987 Mar; 205(3):302-4. PubMed ID: 3030201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.
    McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A
    Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors.
    Forconi C; Gatault P; Miquelestorena-Standley E; Noble J; Al-Hajj S; Guillemain R; Stern M; Hoffmann T; Prat L; Suberbielle C; Masson E; Cesbron-Gautier A; Gaudy-Graffin C; Goudeau A; Thibault G; Ivanes F; Guibon R; Kazma I; Lebranchu Y; Büchler M; Magnan A; Halimi JM; Baron C
    J Heart Lung Transplant; 2017 Mar; 36(3):315-324. PubMed ID: 27751774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
    Mabilangan C; Preiksaitis JK; Cervera C;
    Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor-specific transfusion and living-related donor transplantation. A multicenter evaluation.
    Weir MR; Henry ML; Blackmore M; Smith J; First MR; Irwin B; Shen S; Genemans G; Alexander JW; Corry RJ
    Transplantation; 1988 Jan; 45(1):111-6. PubMed ID: 2827352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3.
    Hibberd PL; Tolkoff-Rubin NE; Cosimi AB; Schooley RT; Isaacson D; Doran M; Delvecchio A; Delmonico FL; Auchincloss H; Rubin RH
    Transplantation; 1992 Jan; 53(1):68-72. PubMed ID: 1310173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
    Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
    BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.